Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24007686 | 0.82 | MCL1 (0.45) | SMN1; SMN2TP53ALOX15MAPK1HPGD | |
| SCHEMBL28389237 | 0.79 | ALDH1A1 (0.40) | SMN1; SMN2TP53HSD17B10ALDH1A1KMT2A | |
| SCHEMBL923978 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2TP53HSD17B10ALDH1A1KMT2A | |
| SCHEMBL1490037 | 0.73 | HPGD (0.47) | SMN1; SMN2TP53ALOX15MAPK1HSD17B10 | |
| SCHEMBL30442982 | 0.73 | ALOX15 (0.43) | SMN1; SMN2TP53ALOX15MAPK1HSD17B10 | |
| SCHEMBL20108 | 0.73 | ALOX15 (0.43) | SMN1; SMN2TP53ALOX15MAPK1HSD17B10 | |
| SCHEMBL22109258 | 0.73 | ALDH1A1 (0.46) | SMN1; SMN2TP53HSD17B10ALDH1A1KMT2A | |
| SCHEMBL22861454 | 0.71 | ALOX15 (0.42) | SMN1; SMN2TP53ALOX15MAPK1HSD17B10 | |
| Lithium SCHEMBL31258223 | 0.71 | ALOX15 (0.42) | SMN1; SMN2TP53ALOX15MAPK1HSD17B10 | |
| SCHEMBL21614018 | 0.71 | ALOX15 (0.42) | SMN1; SMN2TP53ALOX15MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | claimed |
| EP-4430042-B1 | 6-HETERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025228892-A1 | MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| US-20250333414-A1 | HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2025-10-30 | — | — | US | disclosed |
| US-20250333398-A1 | MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2025-10-30 | — | — | US | disclosed |
| US-12419885-B2 | Kinase inhibitors and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| EP-4568951-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025119300-A1 | MYT1 KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 广东东阳光药业股份有限公司 | 2025-06-12 | — | — | WO | disclosed |
| CN-120118088-A | Myt1 kinase inhibitor compounds, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-102112467-A | Compounds and compositions as kinase inhibitors | IRM LLC | 2011-06-29 | — | — | CN | disclosed |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| EP-2318392-A2 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-11 | — | — | EP | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010002655-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-01-07 | — | — | WO | disclosed |
| CN-1034333-C | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents | SANKYO CO (JP) | 1997-03-26 | — | — | CN | disclosed |
| CN-1032207-C | Imidazopyrazole derivatives useful as analgesics and anti-inflammatory agents | SANKYO CO (JP) | 1996-07-03 | — | — | CN | disclosed |
| CN-1094049-A | Be used as the preparation method of the imidazolopyrazole derivatives of anodyne and antiphlogistic | SANKYO CO (JP) | 1994-10-26 | — | — | CN | disclosed |
| CN-1040196-A | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents | SANKYO CO (JP) | 1990-03-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | SMN1; SMN2 4367/4885TP53 2342/4885ALOX15 1712/4885 |
| US-20250333414-A1 | HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | STING1, MAVS, TBK1 | SMN1; SMN2 4173/4885TP53 1242/4885ALOX15 161/4885 |
| US-12419885-B2 | Kinase inhibitors and methods of use thereof | GSK3B, GSK3A, CSNK1A1 | SMN1; SMN2 1580/4885TP53 1485/4885ALOX15 3118/4885 |
| US-20250333398-A1 | MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | STING1, MAVS, TBK1 | SMN1; SMN2 4117/4885TP53 1933/4885ALOX15 220/4885 |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | CDK2, PHKG1, PHKG2 | SMN1; SMN2 4751/4885TP53 2050/4885ALOX15 2868/4885 |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, TYMP, PDXK | SMN1; SMN2 1909/4885TP53 795/4885ALOX15 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.